Premium
The peripheral messenger RNA expression of glycogen synthase kinase‐3β genes in Alzheimer's disease patients: a preliminary study
Author(s) -
SHENG JianHua,
NG TzePin,
LI ChunBo,
LU GuangHua,
HE Wei,
QIAN YiPing,
WANG JingHua,
YU ShunYing
Publication year - 2012
Publication title -
psychogeriatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 32
eISSN - 1479-8301
pISSN - 1346-3500
DOI - 10.1111/j.1479-8301.2012.00426.x
Subject(s) - gsk 3 , gene expression , messenger rna , gene , real time polymerase chain reaction , disease , taqman , gsk3b , medicine , biology , kinase , endocrinology , psychology , oncology , genetics
Objective: To explore the peripheral leucocytic messenger RNA (mRNA) expression of glycogen synthase kinase‐3β ( GSK‐3β ) gene in Alzheimer's disease (AD) patients. Methods: Using TaqMan relative quantitative real‐time polymerase chain reaction, we analyzed leucocytic gene expression of GSK‐3β in 48 AD patients and 49 healthy controls. Clinical data of AD patients were also collected. Results: The mRNA expression level of the GSK‐3β gene was significantly higher in the AD group (3.13 ± 0.62) than in the normal group (2.77 ± 0.77). Correlational analyses showed that the mRNA expression level of GSK‐3β gene in AD patients was associated with the age of onset ( P = 0.047), age ( P = 0.055), and Behavioral Pathology in Alzheimer's Disease Rating Scale total score ( P = 0.062) and subscores: aggressiveness score ( P = 0.073) and anxieties and phobias score ( P = 0.067). Through multivariate regression model, older age, higher anxieties and phobias score and aggressiveness score were associated with higher mRNA expression level of GSK‐3β gene. Conclusion: In AD patients, the mRNA expression level of the GSK‐3β gene is increased and may be related to age and behavioural pathology in AD.